BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Corcept Therapeutics Inc. (Nasdaq: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/cort. What is this all about? Shares of Corcept Therapeutics fell 16% in pre-market trading on January 30, after a report highlighted language in th ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of BlackRock TCP Capital Corp. ("BlackRock†or the "Company†) (NASDAQ: TCPC) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BLACKROCK TCP CAPITAL CORP. (TCPC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On January 23, 2026, after market hours, BlackR. ...

STEL MERGER INVESTIGATION: Halper Sadeh LLC is Investigating Whether the Sale of Stellar Bancorp, Inc. is Fair to ShareholdersJan 28, 2026 10:32 AM Eastern Standard Time# STEL MERGER INVESTIGATION: Halper Sadeh LLC is Investigating Whether the Sale of Stellar Bancorp, Inc. is Fair to ShareholdersShare---Shareholders may contact the firm to discuss their rights.NEW YORK--([BUSINESS WIRE])--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Stellar Bancorp, Inc. (NYSE: STEL) t ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Gold Resource Corporation (NYSE American: GORO) to Goldgroup Mining Inc. for 1.4476 common shares of Goldgroup for each share of Gold Resource common stock is fair to Gold Resource shareholders. Halper Sadeh encourages Gold Resource shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or z ...

SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Wealthfront Corporation (NASDAQ: WLTH). If you have information that could assist in the Wealthfront investigation or if you are a Wealthfront investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-wealthfront-corporation-investigation-wlth.html You can also contact attorney J.C. ...

法律调查启动 - 律师事务所Levi & Korsinsky已对Bgin Blockchain Limited启动调查 涉及潜在违反联邦证券法的行为 [1] 公司财务表现恶化 - 公司于2025年11月14日发布了截至2025年6月30日的六个月未经审计财务业绩 [2] - 总营收较上年同期大幅下降约9600万美元 [2] - 营业费用激增582.8% [2] - 公司毛利润从上一年度的8480万美元暴跌至毛亏损630万美元 [2] 审计师变更与市场反应 - 公司于2025年12月15日披露 决定不再续聘或就续约与其现任审计师谈判新条款 并已批准聘请一家新的独立注册会计师事务所 自2025年12月12日起生效 [3] - 此消息公布后 公司股价在2025年12月29日暴跌超过59% [3] 律师事务所背景 - Levi & Korsinsky是一家全国知名的证券诉讼律师事务所 在过去20年里为受损股东追回了数亿美元 [5] - 该事务所在复杂证券诉讼中代表投资者方面拥有丰富经验 拥有超过70名员工 [5] - 连续七年被ISS证券集体诉讼服务评为美国顶级证券诉讼律师事务所之一 [5]

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Inovio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Dece ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of RAPT Therapeutics, Inc. (NASDAQ: RAPT) to GSK plc for $58.00 per share is fair to RAPT shareholders. Halper Sadeh encourages RAPT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether RAPT and its board of directors violated th ...

事件概述 - Levi & Korsinsky律师事务所宣布已对Corcept Therapeutics Incorporated启动调查 调查内容涉及该公司可能违反联邦证券法的行为 [1] 监管与产品进展 - 2025年12月31日 Corcept公司宣布其新药relacorilant的申请收到美国食品药品监督管理局的完整回复函 该申请旨在治疗继发于皮质醇增多症的高血压患者 但未获批准 [1] - 美国食品药品监督管理局认可了此前GRACE和GRADIENT药物试验的结果 但得出结论认为 在Corcept未提供额外有效性证据的情况下 无法对relacorilant做出有利的获益-风险评估 [2] 市场反应 - 受上述消息直接影响 Corcept公司股价在2025年12月31日开盘时大幅下跌 每股下跌31.42美元 跌幅达44.76% 开盘价报每股38.78美元 [2] - 此次下跌使Corcept股价创下52周新低 跌至自2024年9月以来未见过的水平 [3]

事件概述 - 律师事务所Kirby McInerney LLP提醒投资者 其正代表Soleno Therapeutics Inc (NASDAQ: SLNO)的投资者 就公司及/或其高级管理层可能违反联邦证券法或其他非法商业行为进行调查 [1] 事件时间线与市场影响 - 2025年8月15日 Scorpion Capital发布报告 指称Soleno的唯一产品Vykat XR定价过高且对儿童可能不安全 此消息导致Soleno股价从2025年8月14日的每股77.36美元下跌5.73美元 跌幅约7.41% 至2025年8月15日收盘价每股71.64美元 [3] - 2025年11月4日 Soleno在季度财报电话会议中披露 截至2025财年第三季度末 因不良反应导致的Vykat XR停药率约为8% 公司首席执行官承认 在8月中旬卖空报告发布后 Vykat XR的上市轨迹受到干扰 主要表现为新患者起始表单数量减少以及因非严重不良事件导致的停药增加 此消息导致Soleno股价从2025年11月4日的每股63.85美元下跌16.98美元 跌幅约26.59% 至2025年11月5日收盘价每股46.87美元 [4] 公司产品与运营状况 - Soleno的唯一产品为Vykat XR [3] - 卖空报告及后续披露的不良反应停药率对Vykat XR的上市轨迹产生了实质性干扰 [4]